DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Rhumbline Advisers

Rhumbline Advisers lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 3.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 776,229 shares of the medical device company's stock after selling 29,434 shares during the quarter. Rhumbline Advisers owned 0.20% of DexCom worth $60,367,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of DXCM. Geode Capital Management LLC grew its holdings in DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company's stock worth $664,056,000 after acquiring an additional 214,136 shares in the last quarter. Jennison Associates LLC lifted its position in shares of DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after purchasing an additional 710,858 shares during the last quarter. Groupama Asset Managment grew its stake in shares of DexCom by 1.1% during the third quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company's stock worth $1,912,000 after purchasing an additional 31,358 shares in the last quarter. Westfield Capital Management Co. LP increased its holdings in DexCom by 44.6% in the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock valued at $190,532,000 after buying an additional 876,739 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in DexCom by 11.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company's stock valued at $183,298,000 after buying an additional 288,381 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company's stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the business's stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 38,083 shares of company stock valued at $3,309,794. Company insiders own 0.30% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on DXCM shares. Citigroup lifted their price target on DexCom from $85.00 to $91.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and raised their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. StockNews.com downgraded DexCom from a "buy" rating to a "hold" rating in a report on Saturday, November 2nd. Royal Bank of Canada cut their price objective on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Finally, Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $99.06.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded down $0.34 on Thursday, reaching $89.34. The company's stock had a trading volume of 3,340,349 shares, compared to its average volume of 3,629,892. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The stock has a market capitalization of $34.90 billion, a P/E ratio of 62.48, a PEG ratio of 2.33 and a beta of 1.14. The stock's 50-day moving average is $83.06 and its two-hundred day moving average is $75.85. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, sell-side analysts forecast that DexCom, Inc. will post 2.02 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.